Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2007

View Archived Issues

Pramipexole shows potential in treatment-resistant depression

Recent patents describe new therapeutic agents for diabetes

Protease-mediated CXCR1 cleavage increases infection risk in cystic fibrosis lung disease

LPA1: a novel therapeutic target for idiopathic pulmonary fibrosis

New antiinfective agents disclosed in recent patent literature

Basilea files Canadian New Drug Submission for alitretinoin for chronic hand eczema

Progen's phase III study of PI-88 for HCC open for recruitment

Diamyd files IND with FDA for phase III clinical trial of Diamyd for type 1 diabetes

Lundbeck and Paion expand license agreement for desmoteplase

Medivir and Presidio amend MIV-310 license agreement

Phase I trial commences for Cougar Biotechnology's CB-3304

AVI BioPharma starts dosing in Duchenne muscular dystrophy trial

Pharming requests re-examination of CHMP opinion for Rhucin

Eisai commences cash tender offer for outstanding MGI shares

Cubist acquires Illumigen Biosciences

Fresenius applies for marketing authorization of Removab for malignant ascites

Preliminary phase II results reported for Sinovac's pandemic influenza vaccine

Cell Therapeutics completes Zevalin's acquisition for U.S. sales and marketing

CytRx initiates phase IIb trial with arimoclomol for the treatment of ALS

Galvus obtains positive opinion regarding E.U. prescribing information changes

Endocyte and R&D-Biopharmaceuticals enter tubulysin chemo agent agreement

Collegium reports results for its abuse deterrent sustained release opioid study

Immtech's pafuramidine program on clinical hold

Antisense provides update on ATL-1102 phase IIa multiple sclerosis trial

PharmaMar's Yondelis completes requirements for launch in Spain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...